Our Leadership Team
|
Peter Staehr, MD
Interim Chief Medical Officer Peter Staehr, MD, is a senior executive medical doctor with 20+ years of global clinical development experience and executive management in Pharmaceutical/Biotech as well as Medical Drug-Device combination. He was trained as internist and cardiologist at Johannes-Gutenberg University Mainz, Germany, and completed his postdoc fellowship at Stanford University. Dr. Staehr held leadership roles in early- and late-stage (Phase 1-3) clinical development with increasing responsibilities at small to large-size organizations (J&J, Theravance, CV Therapeutics, Gilead, Abbott Vascular, ChemoCentryx). As the medical lead he oversaw numerous IND drug development programs in various therapeutic areas and was directly involved in the registration of Regadenoson (LexiscanÒ) and Abbott’s Absorb™ bioresorbable stent. Dr. Staehr is the consulting CMO of two companies including Renexxion. He also serves as the chairman of the San Francisco Bay Area chapter of the Pharmaceutical & BioScience Society (PBSS).
|